Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra Low Dose Radiation Prior or After Chemotherapy Free Targeted Therapy for Relapsed/Refractory Mantle Cell Lymphoma
NCT04054167Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2019
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall response rate at 3 months. Started Jun 2019; status: active, not recruiting.
02
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04054167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04054167.